Ikena Oncology, Inc. is a clinical stage biotechnology company, which engages in the development of patient directed and biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412, and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, MA.
相关临床试验
6
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2016
已完成
2
33.3%
终止
3
50.0%
撤回
1
16.7%
暂无批准数据
- Remedy Plan Therapeutics appointed Jotin Marango, M.D., Ph.D., as Chief Financial and Business Officer to strengthen financial position and advance corporate goals. - Dr. Marango brings over 15 years of biotechnology experience, including leadership roles at Ikena Oncology and Aptose Biosciences in hematology and oncology. - The appointment comes as the company advances its lead NAMPT inhibitor RPT1G through Phase 1 trials for relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes. - RPT1G utilizes a unique hyperbolic inhibition mechanism designed to overcome historical toxicity limitations of NAMPT inhibitors while targeting cancer cell metabolism.
- DISCO Pharmaceuticals appointed Mark Manfredi as CEO and closed a €36 million seed financing round co-led by Ackermans & van Haaren and NRW.Bank to advance surfaceome-targeted therapies. - The company's proprietary platform identifies novel cell-surface target pairs to develop bispecific antibody-drug conjugates and T-cell engagers for hard-to-treat tumors. - Lead ADC programs targeting small cell lung cancer and microsatellite-stable colorectal cancer are advancing toward IND-enabling studies and clinical development. - The financing represents an expansion from the company's previous €20 million seed round, with continued support from existing investors including Sofinnova Partners and AbbVie Ventures.
- ImageneBio announced a protocol amendment for its ongoing Phase 2b ADAPTIVE study of IMG-007 in atopic dermatitis to optimize study design and expand dosing regimens based on the drug's unique molecular attributes. - The company will present novel alopecia areata data at the Inflammatory Skin Disease Summit, showing dose-related hair regrowth and biomarker suppression in Phase 1b/2a trials. - IMG-007 demonstrated a 77% mean reduction in EASI score at week 16 in atopic dermatitis patients, with 54% achieving EASI-75 response and 31% reaching EASI-90 response. - The company strengthened its cash position to $142.6 million following completion of a reverse merger and $75 million private placement financing.
- Ikena Oncology and Inmagene Biopharmaceuticals have appointed former Poseida Therapeutics CEO Kristin Yarema to lead the merged company ImageneBio following their anticipated July 2025 closing. - The merger includes a concurrent $75 million private placement and will focus on advancing IMG-007, an anti-OX40 monoclonal antibody that recently completed Phase 2a trials in atopic dermatitis and alopecia areata. - IMG-007 demonstrated sustained clinical activity with a 34.7-day half-life in subcutaneous formulation, supporting potential for infrequent dosing in immunological and inflammatory diseases.
- Hillstar Bio appointed Maude Tessier, Ph.D., as Chief Operating Officer and Shiva Krupa, Ph.D., MBA, as Vice President of Program Management to strengthen leadership capabilities. - The strategic hires support advancement of the company's lead TRBV9 program for axial spondyloarthritis treatment toward clinical entry in 2026. - Tessier brings 18 years of biopharmaceutical experience including successful financing and partnership leadership, while Krupa contributes extensive R&D program management expertise. - The company recently secured $67 million in Series A financing and focuses on precision immunology approaches that selectively target pathogenic immune cells while sparing healthy ones.
• Major pharmaceutical companies including Pfizer, Novartis, and Takeda have implemented significant workforce reductions over the past year due to patent cliffs and economic pressures. • Unlike previous trends, current layoffs are heavily impacting R&D departments, marking a shift from traditional commercial-focused cuts and reflecting the industry's evolving outsourcing landscape. • Contract Research Organizations (CROs) are benefiting from the industry shift, absorbing displaced talent and gaining additional business as pharmaceutical companies restructure their operations.
